Telix HY26 Results Presentation
Filed with ASX · · 27 pages · English
Telix Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Telix Pharmaceuticals
- Telix HY26 Appendix 4D and Interim Report
- Telix to Host R&D Day in New York City on September 22, 2026
- Telix H1 2026 Results: Investor Webcast Notification
- TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
- Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
Later from Telix Pharmaceuticals
- Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
- Telix Appoints David Gill as Chair
- Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
- Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference
- FDA Approves Telix Brain Cancer Imaging Drug Pixclara
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals